Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Analytics

Trial Phases

No phase data

Trial Status

Completed14

Recruiting1

Other1

Role Distribution

Other Roles16

Activity Timeline

Clinical Trials (16)

NCT05665374Completed

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

StudydirectorStart date: 2023-06-19

NCT05835778Completed

Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Biliary Tract Cancer

StudydirectorStart date: 2023-06-06

NCT05826366Completed

Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Carcinoma, Non-Small-Cell Lung

StudydirectorStart date: 2023-06-02

NCT05667064Completed

Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Unresectable Hepatocellular Carcinoma

StudydirectorStart date: 2023-05-09

NCT05729711Active Not Recruiting

TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)

StudydirectorStart date: 2023-04-04

NCT05677308Completed

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

Breast Cancer

StudydirectorStart date: 2023-03-07

NCT05687877Completed

Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)

SARS-CoV-2 Infection

StudydirectorStart date: 2023-01-06

NCT05454787Recruiting

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)

Factor Xa InhibitorLife Threatening Bleeding

StudydirectorStart date: 2022-06-02

NCT05306210Completed

Forxiga CKD Japan Post-Marketing Surveillance (PMS)

Chronic Kidney Disease

StudydirectorStart date: 2022-04-12

NCT04872621Completed

Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)

StudydirectorStart date: 2021-06-30

Showing 10 of 16 trials

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Breast Cancer2 Carcinoma, Non-Small-Cell Lung2 Asthma1 Biliary Tract Cancer1 Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)1 Carcinoma, Small Cell1 Chronic Kidney Diseases1 Factor Xa Inhibitors1

Affiliations

Astrazeneca KK

AstraZeneca KK

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Dong-Xin Wang, MD, PhD

Peking University First Hospital

74 trials

Shared therapeutic areas:

Breast CancerCarcinoma, Non-Small-Cell LungChronic Kidney Diseases

Similarity Score6%

Melda Saglam, PhD

Hacettepe University

14 trials

Shared therapeutic areas:

Breast CancerChronic Kidney DiseasesCOVID-19

Similarity Score6%

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

21 trials

Shared therapeutic areas:

Breast CancerCarcinoma, Non-Small-Cell LungOvary Cancer

Similarity Score6%

Mark Levine, MD

Ontario Clinical Oncology Group (OCOG)

13 trials

Shared therapeutic areas:

Breast CancerCarcinoma, Non-Small-Cell LungOvary Cancer

Similarity Score6%

Shirley Wang, PhD, ScM

Brigham and Women's Hospital

51 trials

Shared therapeutic areas:

AsthmaChronic Kidney DiseasesCarcinoma, Non-Small-Cell Lung

Similarity Score6%

Ali MA Ismail, lecturer

Cairo University

27 trials

Shared therapeutic areas:

AsthmaBreast Cancer

Similarity Score4%

Hagop Youssoufian, MD

Verastem, Inc.

20 trials

Shared therapeutic areas:

AsthmaOvary Cancer

Similarity Score4%

Francesco Perrone, M.D., Ph.D.

National Cancer Institute, Naples

13 trials

Shared therapeutic areas:

Ovary CancerCarcinoma, Non-Small-Cell Lung

Similarity Score4%

Rahul Aggarwal, MD

University of California, San Francisco

22 trials

Shared therapeutic areas:

Carcinoma, Non-Small-Cell LungCarcinoma, Small Cell

Worked with same sponsors:

AstraZeneca

Similarity Score4%

Naciye Vardar-Yagli, PhD

Hacettepe University

14 trials

Shared therapeutic areas:

COVID-19Chronic Kidney Diseases

Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (16)

Showing 16 of 16 trials

NCT05665374StudyDirector

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

Completed

NCT05835778StudyDirector

Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Biliary Tract Cancer

Completed

NCT05826366StudyDirector

Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

Carcinoma, Non-Small-Cell Lung

Completed

NCT05667064StudyDirector

Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Unresectable Hepatocellular Carcinoma

Completed

NCT05729711StudyDirector

TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)

Active Not Recruiting

NCT05677308StudyDirector

LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS)

Breast Cancer

Completed

NCT05687877StudyDirector

Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)

SARS-CoV-2 Infection

Completed

NCT05454787StudyDirector

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)

Factor Xa InhibitorLife Threatening Bleeding

Recruiting

NCT05306210StudyDirector

Forxiga CKD Japan Post-Marketing Surveillance (PMS)

Chronic Kidney Disease

Completed

NCT04872621StudyDirector

Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

Relapsed or Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Lymphoma)

Completed

NCT04889404StudyDirector

LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)

Pancreatic Neoplasms

Completed

NCT04854590StudyDirector

IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

Carcinoma, Small Cell

Completed

NCT03643484StudyDirector

IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy

Carcinoma, Non-Small-Cell Lung

Completed

NCT03590938StudyDirector

Lynparza Breast Cancer Clinical Experience Investigation

Breast Cancer

Completed

NCT03588546StudyDirector

FASENRA SCEI for Long-term Use

Asthma

Completed

NCT03505307StudyDirector

Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)

Ovarian Cancer

Completed

All 16 trials loaded